Neurobiology of Aging
Volume 29, Issue 10 , Pages 1456-1465 , October 2008

PET imaging of amyloid deposition in patients with mild cognitive impairment

  • Anton Forsberg

      Affiliations

    • Karolinska Institute, Department of Neurobiology, Care Sciences and Society, Stockholm, Sweden
    • ,
  • Henry Engler

      Affiliations

    • Department of Nuclear Medicine, Uppsala University Hospital, Uppsala, Sweden
    • ,
  • Ove Almkvist

      Affiliations

    • Karolinska Institute, Department of Neurobiology, Care Sciences and Society, Stockholm, Sweden
    • Department of Geriatric Medicine, Karolinska University Hospital Huddinge, Stockholm, Sweden
    • Department of Psychology, Stockholm University, Stockholm, Sweden
    • ,
  • Gunnar Blomquist

      Affiliations

    • Department of Oncology, Radiology and Clinical Immunology, Uppsala University, Uppsala, Sweden
    • ,
  • Göran Hagman

      Affiliations

    • Department of Geriatric Medicine, Karolinska University Hospital Huddinge, Stockholm, Sweden
    • ,
  • Anders Wall

      Affiliations

    • Uppsala Imanet AB, Imanet, GE Healthcare, Sweden
    • ,
  • Anna Ringheim

      Affiliations

    • Uppsala Imanet AB, Imanet, GE Healthcare, Sweden
    • ,
  • Bengt Långström

      Affiliations

    • Uppsala Imanet AB, Imanet, GE Healthcare, Sweden
    • Department of Biochemistry and Organic Chemistry, Uppsala University, Uppsala, Sweden
    • ,
  • Agneta Nordberg

      Affiliations

    • Karolinska Institute, Department of Neurobiology, Care Sciences and Society, Stockholm, Sweden
    • Department of Geriatric Medicine, Karolinska University Hospital Huddinge, Stockholm, Sweden
    • Corresponding Author InformationCorresponding author at: Karolinska Institutet, Department of Neurobiology, Care Sciences and Society, Division of Molecular Neuropharmacology, Karolinska University Hospital Huddinge, Novum 5th Floor, S-141 86 Stockholm, Sweden. Tel.: +46 8 58585467; fax: +46 8 58585470.

Received 8 January 2007 ,Revised 25 March 2007 ,Accepted 30 March 2007.

References 

  1. American Psychiatric Association . Diagnostic and Statistical Manual of Mental Disorders. forth ed.. Washington, DC: American Psychiatric Association; 1994;
  2. Anchisi D, Borroni B, Franceschi M, Kerrouche N, Kalbe E, Beuthien-Beumann B, et al. Heterogeneity of brain glucose metabolism in mild cognitive impairment and clinical progression to Alzheimer disease. Arch. Neurol. 2005;62(11):1728–1733
  3. Andersson JL, Thurfjell L. Implementation and validation of a fully automatic system for intra- and interindividual registration of PET brain scans. J. Comput. Assist. Tomogr. 1997;21(1):136–144
  4. Andreasen N, Hesse C, Davidsson P, Minthon L, Wallin A, Winblad B, et al. Cerebrospinal fluid beta-amyloid(1-42) in Alzheimer disease: differences between early- and late-onset Alzheimer disease and stability during the course of disease. Arch. Neurol. 1999;56(6):673–680
  5. Archer HA, Edison P, Brooks DJ, Barnes J, Frost C, Yeatman T, et al. Amyloid load and cerebral atrophy in Alzheimer's disease: an 11C-PIB positron emission tomography study. Ann. Neurol. 2006;60(1):145–147
  6. Arnaiz E, Almkvist O, Ivnik RJ, Tangalos EG, Wahlund LO, Winblad B, et al. Mild cognitive impairment: a cross-national comparison. J. Neurol. Neurosurg. Psychiatry. 2004;75(9):1275–1280
  7. Arnaiz E, Jelic V, Almkvist O, Wahlund LO, Winblad B, Valind S, et al. Impaired cerebral glucose metabolism and cognitive functioning predict deterioration in mild cognitive impairment. Neuroreport. 2001;12(4):851–855
  8. Bergman I, Blomberg M, Almkvist O. The importance of impaired physical health and age in normal cognitive aging. Scand. J. Psychol. 2007;48:115–125
  9. Blennow K, Hampel H. CSF markers for incipient Alzheimer's disease. Lancet Neurol. 2003;2(10):605–613
  10. Blennow K, Wallin A, Agren H, Spenger C, Siegfried J, Vanmechelen E. Tau protein in cerebrospinal fluid: a biochemical marker for axonal degeneration in Alzheimer disease?. Mol. Chem. Neuropathol. 1995;26(3):231–245
  11. Buerger K, Teipel SJ, Zinkowski R, Sunderland T, Andreasen N, Blennow K, et al. Increased levels of CSF phosphorylated tau in apolipoprotein E varepsilon4 carriers with mild cognitive impairment. Neurosci. Lett. 2005;
  12. Chetelat G, Baron JC. Early diagnosis of Alzheimer's disease: contribution of structural neuroimaging. Neuroimage. 2003;18(2):525–541
  13. Chetelat G, Desgranges B, De La Sayette V, Viader F, Eustache F, Baron JC. Mild cognitive impairment: can FDG-PET predict who is to rapidly convert to Alzheimer's disease?. Neurology. 2003;60(8):1374–1377
  14. de Leon MJ, DeSanti S, Zinkowski R, Mehta PD, Pratico D, Segal S, et al. Longitudinal CSF and MRI biomarkers improve the diagnosis of mild cognitive impairment. Neurobiol. Aging. 2006;27(3):394–401
  15. Drzezga A, Lautenschlager N, Siebner H, Riemenschneider M, Willoch F, Minoshima S, et al. Cerebral metabolic changes accompanying conversion of mild cognitive impairment into Alzheimer's disease: a PET follow-up study. Eur. J. Nucl. Med. Mol. Imaging. 2003;30(8):1104–1113
  16. Edison P, Archer HA, Hinz R, Hammers A, Pavese N, Tai YF, et al. Amyloid hypometabolism, and cognition in Alzheimer disease. An [11C]PIB and [18F]FDGPET study. Neurology. 2006;
  17. Engler H, Forsberg A, Almkvist O, Blomquist G, Larsson E, Savitcheva I, et al. Two-year follow-up of amyloid deposition in patients with Alzheimer's disease. Brain. 2006;129(Pt. 11):2856–2866
  18. Engler H, Lundberg PO, Ekbom K, Nennesmo I, Nilsson A, Bergstrom M, et al. Multitracer study with positron emission tomography in Creutzfeldt-Jakob disease. Eur. J. Nucl. Med. Mol. Imaging. 2003;30(1):85–95
  19. Fagan AM, Mintun MA, Mach RH, Lee SY, Dence CS, Shah AR, et al. Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta(42) in humans. Ann. Neurol. 2006;59(3):512–519
  20. Folstein MF, Folstein SE, McHugh PR. Mini-mental state. A practical method for grading the cognitive state of patients for the clinician. J. Psychiatry Res. 1975;12(3):189–198
  21. Galvin JE, Powlishta KK, Wilkins K, McKeel DW, Xiong C, Grant E, et al. Predictors of preclinical Alzheimer disease and dementia: a clinicopathologic study. Arch. Neurol. 2005;62(5):758–765
  22. Hansson O, Zetterberg H, Buchhave P, Londos E, Blennow K, Minthon L. Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study. Lancet Neurol. 2006;5(3):228–234
  23. Herukka SK, Hallikainen M, Soininen H, Pirttila T. CSF Abeta42 and tau or phosphorylated tau and prediction of progressive mild cognitive impairment. Neurology. 2005;64(7):1294–1297
  24. Kemppainen NM, Aalto S, Wilson IA, Nagren K, Helin S, Bruck A, et al. Voxel-based analysis of PET amyloid ligand [11C]PIB uptake in Alzheimer disease. Neurology. 2006;67(9):1575–1580
  25. Klunk WE, Engler H, Nordberg A, Wang Y, Blomqvist G, Holt DP, et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol. 2004;55(3):306–319
  26. Klunk WE, Wang Y, Huang GF, Debnath ML, Holt DP, Mathis CA. Uncharged thioflavin-T derivatives bind to amyloid-beta protein with high affinity and readily enter the brain. Life Sci. 2001;69(13):1471–1484
  27. Kordower JH, Chu Y, Stebbins GT, DeKosky ST, Cochran EJ, Bennett D, et al. Loss and atrophy of layer II entorhinal cortex neurons in elderly people with mild cognitive impairment. Ann. Neurol. 2001;49(2):202–213
  28. Lezak MD. In: Neuropsychological Assessment. third ed.. New York: Oxford Univ. Press; 1995;pp. 1026
  29. Lopresti BJ, Klunk WE, Mathis CA, Hoge JA, Ziolko SK, Lu X, et al. Simplified quantification of Pittsburgh compound B amyloid imaging PET studies: a comparative analysis. J. Nucl. Med. 2005;46(12):1959–1972
  30. Mathis CA, Wang Y, Holt DP, Huang GF, Debnath ML, Klunk WE. Synthesis and evaluation of 11C-labeled 6-substituted 2-arylbenzothiazoles as amyloid imaging agents. J. Med. Chem. 2003;46(13):2740–2754
  31. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology. 1984;34(7):939–944
  32. Mintun MA, Larossa GN, Sheline YI, Dence CS, Lee SY, Mach RH, et al. [11C]PIB in a nondemented population: potential antecedent marker of Alzheimer disease. Neurology. 2006;67(3):446–452
  33. Mirra SS, Gearing M, McKeel DW, Crain BJ, Hughes JP, van Belle G, et al. Interlaboratory comparison of neuropathology assessments in Alzheimer's disease: a study of the Consortium to Establish a Registry for Alzheimer's Disease (CERAD). J. Neuropathol. Exp. Neurol. 1994;53(3):303–315
  34. Morris JC, Storandt M, Miller JP, McKeel DW, Price JL, Rubin EH, et al. Mild cognitive impairment represents early-stage Alzheimer disease. Arch. Neurol. 2001;58(3):397–405
  35. Patlak CS, Blasberg RG, Fenstermacher JD. Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data. J. Cereb. Blood Flow Metab. 1983;3(1):1–7
  36. Petersen RC. Mild cognitive impairment as a diagnostic entity. J. Intern. Med. 2004;256(3):183–194
  37. Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangalos EG, Kokmen E. Mild cognitive impairment: clinical characterization and outcome. Arch. Neurol. 1999;56(3):303–308
  38. Shoghi-Jadid K, Small GW, Agdeppa ED, Kepe V, Ercoli LM, Siddarth P, et al. Localization of neurofibrillary tangles and beta-amyloid plaques in the brains of living patients with Alzheimer disease. Am. J. Geriatr. Psychiatry. 2002;10(1):24–35
  39. Small GW, Kepe V, Ercoli LM, Siddarth P, Bookheimer SY, Miller KJ, et al. PET of brain amyloid and tau in mild cognitive impairment. N. Engl. J. Med. 2006;355(25):2652–2663
  40. Storandt M, Grant EA, Miller JP, Morris JC. Rates of progression in mild cognitive impairment and early Alzheimer's disease. Neurology. 2002;59(7):1034–1041
  41. Vanmechelen E, Vanderstichele H, Davidsson P, Van Kerschaver E, Van Der Perre B, Sjogren M, et al. Quantification of tau phosphorylated at threonine 181 in human cerebrospinal fluid: a sandwich ELISA with a synthetic phosphopeptide for standardization. Neurosci. Lett. 2000;285(1):49–52
  42. Verhoeff NP, Wilson AA, Takeshita S, Trop L, Hussey D, Singh K, et al. In-vivo imaging of Alzheimer disease beta-amyloid with [11C]SB-13 PET. Am. J. Geriatr. Psychiatry. 2004;12(6):584–595
  43. Visser PJ, Scheltens P, Verhey FR. Do MCI criteria in drug trials accurately identify subjects with predementia Alzheimer's disease?. J. Neurol. Neurosurg. Psychiatry. 2005;76(10):1348–1354
  44. Winblad B, Palmer K, Kivipelto M, Jelic V, Fratiglioni L, Wahlund LO, et al. Mild cognitive impairment-bey ond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment. J. Intern. Med. 2004;256(3):240–246
  45. Yamaguchi H, Hirai S, Morimatsu M, Shoji M, Nakazato Y. Diffuse type of senile plaques in the cerebellum of Alzheimer-type dementia demonstrated by beta protein immunostain. Acta Neuropathol. (Berl.). 1989;77(3):314–319
  46. Ziolko SK, Weissfeld LA, Klunk WE, Mathis CA, Hoge JA, Lopresti BJ, et al. Evaluation of voxel-based methods for the statistical analysis of PIB PET amyloid imaging studies in Alzheimer's disease. Neuroimage. 2006;33(1):94–102

PII: S0197-4580(07)00139-X

doi: 10.1016/j.neurobiolaging.2007.03.029

Neurobiology of Aging
Volume 29, Issue 10 , Pages 1456-1465 , October 2008

Article Tools

* Image Usage & Resolution